Cargando…
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
: DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As with any biologic product, DAXI may potentiall...
Autores principales: | Humphrey, Shannon, Dover, Jeffrey S, Bowsher, Ronald R, Clancy, Amanda, Liu, Yan, Prawdzik, Gregg, Gallagher, Conor J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501746/ https://www.ncbi.nlm.nih.gov/pubmed/37051886 http://dx.doi.org/10.1093/asj/sjad101 |
Ejemplares similares
-
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
por: Gallagher, Conor J., et al.
Publicado: (2023) -
Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position
por: Bertucci, Vince, et al.
Publicado: (2022) -
Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
por: Glogau, Richard, et al.
Publicado: (2021) -
Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA
por: Dover, Jeffrey S., et al.
Publicado: (2023) -
Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines
por: Solish, Nowell, et al.
Publicado: (2022)